An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
LENSAR, Inc. (Nasdaq: LNSR) will release its third quarter 2023 financial results on November 9, 2023. The company specializes in femtosecond laser solutions for cataract treatment. A conference call and webcast will be held at 8:30 am ET to discuss the results and recent corporate highlights.
Positive
None.
Negative
None.
ORLANDO, Fla.--(BUSINESS WIRE)--
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2023 financial results will be released before market open on Thursday, November 9, 2023. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, November 9, 2023 to discuss the financial results and recent corporate highlights.
To participate by telephone, please dial (888) 660 5501 (Domestic) or (646) 960 0416 (International). The conference ID number is 7303394. To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com. Following the live webcast, an archived version of the call will be available on the website.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of visually significant astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY® Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging and software, with an extremely fast dual-pulse femtosecond laser in a compact, highly ergonomic system. ALLY is designed to transform cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
When will LENSAR release its third quarter 2023 financial results?
LENSAR will release its third quarter 2023 financial results on Thursday, November 9, 2023.
What is LENSAR's focus as a medical technology company?
LENSAR is focused on advanced femtosecond laser solutions for the treatment of cataracts.
When and how can I participate in the conference call and webcast?
The conference call and webcast will be held at 8:30 am ET on Thursday, November 9, 2023. To participate by telephone, dial (888) 660 5501 (Domestic) or (646) 960 0416 (International). The conference ID number is 7303394. To access the live webcast, visit the Investors section of LENSAR's website at www.lensar.com.
Will the conference call be available for replay?
Yes, an archived version of the conference call will be available on LENSAR's website after the live webcast.